

Justification Document for the Selection of a CoRAP Substance

Substance Name (public 4-methylanisole name):

EC Number: 203-253-7

CAS Number: 104-93-8

Authority: Health & Safety Authority, Ireland

Date: 17/03/2021

Cover Note

This document has been prepared by the evaluating Member State given in the CoRAP update

1	IDENTITY OF THE SUBSTANCE	3
1.1	Other identifiers of the substance	3
1.2	Similar substances/grouping possibilities	3
2	OVERVIEW OF OTHER PROCESSES / EU LEGISLATION	4
3	HAZARD INFORMATION (INCLUDING CLASSIFICATION)	5
3	Classification .1.1 Harmonised Classification in Annex VI of the CLP .1.2 Self classification .1.3 Proposal for Harmonised Classification in Annex VI of the CLP	5 5 6
4	INFORMATION ON (AGGREGATED) TONNAGE AND USES	6
4.1	Tonnage and registration status	6
4.2	Overview of uses	7
	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE RAP SUBSTANCE	E 8
5.1	. Legal basis for the proposal	8
5.2 CoF	. Selection criteria met (why the substance qualifies for being in RAP)	8
	. Initial grounds for concern to be clarified under Substance luation	8
5.4 req	. Preliminary indication of information that may need to be uested to clarify the concern	9
5.5	. Potential follow-up and link to risk management	9

1 IDENTITY OF THE SUBSTANCE


1.1 Other identifiers of the substance

Table: Other Substance identifiers

EC name (public):	4-methylanisole
IUPAC name (public):	1-methoxy-4-methylbenzene
Index number in Annex VI of the CLP Regulation:	Not applicable
Molecular formula:	C ₈ H ₁₀ O
Molecular weight or molecular weight range:	122.1644
Synonyms:	Anisole, p-methyl- (8CI) Benzene, 1-methoxy-4-methyl- (9CI) Methyl p-methylphenyl ether Methyl p-tolyl ether p-Cresol methyl ether p-Methoxytoluene p-Methylanisol p-Methylanisole p-Tolyl methyl ether

Type of	substance	oxtimes Mon	o-constituent		nstituent	
---------	-----------	-------------	---------------	--	-----------	--

Structural formula:



1.2 Similar substances/grouping possibilities

Not Applicable.

2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION

Table: Completed or ongoing processes

RMOA	☐ Risk Manag	☐ Risk Management Option Analysis (RMOA)			
		☐ Compliance check			
	Evaluation	☐ Testing proposal			
REACH		☑ CoRAP and Substance Evaluation			
Processes	A the a i a a ti a	☐ Candidate List			
	Authorisation	☐ Annex XIV			
	Restriction	☐ Annex XVII¹			
CLH	☐ Annex VI (CLP) (see section 3.1)			
	☐ Plant Prote	ction Products Regulation			
Processes under other	Regulation (EC) No 1107/2009				
EU legislation	☐ Biocidal Product Regulation				
	Regulation	(EU) 528/2012 and amendments			
Previous	☐ Dangerous	substances Directive 67/548/EEC (NONS)			
legislation	☐ Existing Su	bstances Regulation 793/93/EEC (RAR/RRS)			
(UNEP) Stockholm	☐ Assessmen	t			
convention (POPs Protocol)	☐ In relevant Annex				
Other processes/ EU		vide further details below)			
Further details	with initial con toxicity) and of appointed to conthe available need to reques	le was included on the CoRAP for evaluation in 2012, cerns related to developmental toxicity (reproductive exposure. The Competent Authority of Ireland was carry out the evaluation. Based on the evaluation of data, the evaluating MSCA concluded there was a st further information to clarify the concerns relating ental toxicity and worker long-term exposure			

 $^{^{\}scriptsize 1}$ Please specify the relevant entry.

(systemic, inhalation) and therefore prepared a draft decision to request further information.

During the registrants commenting period on the draft decision, the only registrant of the substance informed the evaluating MSCA of their intention to cease manufacture of the substance in accordance with Article 50(3) of REACH. The registration was subsequently revoked and as there were no other registrants of the substance at that time, the substance evaluation decision making process related to the draft decision was terminated and no further information was requested. Therefore, the concern relating to developmental toxicity remained unverified.

As of July 2020, there are 7 active full registration dossiers and 1 individual intermediate registration dossier for this substance, which were submitted since the termination of the original substance evaluation. These registrations include industrial, professional and consumer uses. No additional toxicological data is reported in these registrations and therefore the concern from the original substance evaluation in 2012 relating to developmental toxicity remains unverified.

3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)

3.1 Classification

3.1.1 Harmonised Classification in Annex VI of the CLP

A harmonised classification is not available for this substance.

3.1.2 Self classification

In the registrations:

Flam. Liquid 3 (H226), Acute Tox 4 (H302), Skin Irrit. 2 (H315), Repr. 2 (H361) and Aquatic Chronic 3 (H412).

• The following hazard classes are notified among aggregated self classifications in the C&L Inventory:

Table: Self classification

Index No	International Chemical Identification	EC No	CAS No	Classification		Spec. Conc. Limits,	Notes
				Hazard Class and Category Code(s)	Hazard statement code(s)	M- factors	
				Flam. Liquid 3	H226		
				Acute Tox. 4	H302		
_	4-Methylanisole	203-253-7	104-93-8	Skin Irrit. 2	H315		
_	4-Mediyianisole	203-233-7	104-93-0	Eye Irrit. 2	H319	N/A	
				Acute Tox. 3	H331		
				Repr. 2	H361		
				Aquatic Chronic 3	H412		

3.1.3 Proposal for Harmonised Classification in Annex VI of the CLP

Not relevant.

4 INFORMATION ON (AGGREGATED) TONNAGE AND USES²

4.1 Tonnage and registration status

Table: Tonnage and registration status

From ECHA dissemination site *					
□ Full registration(s) (Art. 10)		☑ Intermediate registration(s) (Art. 17 and/or 18)			
Tonnage band (as per dissemina	ation s	ite)			
□ 1 - 10 tpa	⊠ 1	0 – 100 tpa	□ 100 – 1000 tpa		
□ 1000 – 10,000 tpa	□ 1º	0,000 – 100,000 tpa	□ 100,000 - 1,000,000 tpa		
□ 1,000,000 - 10,000,000 tpa	□ 10 tpa	0,000,000 - 100,000,000	□ > 100,000,000 tpa		
\square <1 >+ tpa (e.g. 10+; 100+; 10,000+ tpa) \square Confidential					
There are 7 active full registrations, which are part of a joint submission and 1 individual intermediate registration.					

*the total tonnage band has been calculated by excluding the intermediate uses, for details see the Manual for Dissemination and Confidentiality under REACH Regulation (section 2.6.11): https://echa.europa.eu/documents/10162/22308542/manual dissemination en.pdf/7e0b87c2-2681-4380-8389-cd655569d9f0

EC No. 203-253-7 MSCA - Ireland Page 6 of 9

² Date when the dissemination site was accessed – 08/07/2020.

4.2 Overview of uses

The substance is used by consumers, by professional workers (widespread uses), in formulation or re-packing, at industrial sites and in manufacturing.

Table: Uses

Part 1:

\boxtimes	\boxtimes	\boxtimes	\boxtimes	\boxtimes	☐ Article	☐ Closed
Manufacture	Formulation	Industrial	Professional	Consumer	service life	system
		use	use	use		

Part 2:

	Use(s)
Uses as intermediate	Intermediate – substance manufactured and used under controlled conditions.
Formulation	Formulation of fragrances and fragrance end products, flavours for tobacco products, polishes and waxes, and washing and cleaning products.
Uses at industrial sites	Industrial use of washing, cleaning and disinfectant products, and metal surface treatment products.
Uses by professional workers	Professional use of polishes and waxes, washing, cleaning and disinfectant products, cosmetics and personal care products.
Consumer Uses	Consumer use of biocides (e.g. disinfectants, pest control products), washing and cleaning products, air care products, polishes and waxes, cosmetics and personal care products, perfumes and fragrances and tobacco products.
Article service life	-

5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE

5.1. Legal basis for the proposal					
☐ Article 45(5)					
5.2. Selection criteria met	(why the substance qualifies	s for being in CoRAP)			
□ Fulfils criteria as CMR/ Suspector	ed CMR				
☐ Fulfils criteria as Sensitiser/ Su	spected sensitiser				
\square Fulfils criteria as potential endo	crine disrupter				
☐ Fulfils criteria as PBT/vPvB / Su	spected PBT/vPvB				
\square Fulfils criteria high (aggregated) tonnage (<i>tpa > 1000</i>)				
□ Fulfils exposure criteria					
$\hfill\Box$ Fulfils MS's (national) priorities					
5.3. Initial grounds for con	cern to be clarified under	r Substance Evaluation			
Hazard based concerns					
CMR □ C □ M ⊠ R	Suspected CMR^1 \square C \square M \square R	☐ Potential endocrine disruptor			
☐ Sensitiser	☐ Suspected Sensitiser³				
☐ PBT/vPvB ☐ Suspected PBT/vPvB¹ ☐ Other (please specify below)					
Exposure/risk based concer	ns				
☐ Wide dispersive use	☐ Consumer use	☐ Exposure of sensitive populations			

☐ Exposure of workers

☐ High (aggregated)

tonnage

☐ Cumulative exposure

 \Box Other (please specify

below)

Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

☐ Exposure of environment

☐ High RCR

³ <u>CMR/Sensitiser</u>: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory) <u>Suspected CMR/Suspected sensitiser</u>: suspected carcinogenic and/or mutagenic and/or reprotoxic properties/suspected sensitising properties (not classified according to CLP harmonized or registrant self-classification)

There are two reproductive/developmental toxicity screening studies with 4-methylanisole reported in the registration data. In a dermal study in rats, no adverse effects were observed in parental animals or offspring up to the highest dose tested, although there were some uncertainties regarding the dosing regimen and the proportion of the applied dose that was systemically available. In an oral study in rats, adverse effects on pre- and post-natal development in the offspring, including an increase in post-implantation loss, a decrease in live birth index and an increase in the number of stillborn pups, were observed. Based on the results of this study, the registrants self classified 4-methylanisole as Repr. 2 H361.

The registration data reports industrial, professional and consumer uses of 4-methylanisole indicating the potential for exposure to humans. Further assessment of the available reproductive toxicity data is required to determine whether additional data to address the reproductive toxicity endpoint is needed and a more stringent hazard classification is warranted. At the registered tonnage band of 4-methylanisole (10-100 tpa), the data requirements relating to reproductive toxicity are limited to a screening study for reproductive/developmental toxicity (OECD 421/422) (Annex VIII, 8.7.1). Following an assessment of all available data under substance evaluation, further information may be requested to investigate the concern for reproductive toxicity (developmental toxicity), which is not possible to request under dossier evaluation at this tonnage band.

5.4. Preliminary indication of information that may need to be requested to clarify the concern

$oxed{\boxtimes}$ Information on toxicological properties	☐ Information on physico-chemical properties
\square Information on fate and behaviour	\square Information on exposure
\square Information on ecotoxicological properties	\square Information on uses
☐ Information ED potential	☐ Other (provide further details below)
Following an assessment of all available data, concern for reproductive toxicity (developmental	

5.5. Potential follow-up and link to risk management

	☐ Restriction	☐ Authorisation	☐ Other (provide further details)
data. Industrial, prof registration data. Cl evaluation could le reproductive toxicity	self-classified the substressional and consumer arification of the concert to the conclusion may be warranted. The prepare the toxicity.	uses of 4-methylanisc rn for reproductive tox that a more string nerefore, depending or	ole are reported in the kicity under substance ent classification for n the outcome of the